نتائج البحث - Alejandro D. Ricart

  • يعرض 1 - 8 نتائج من 8
تنقيح النتائج
  1. 1
    Drug-induced liver injury in Oncology

    Drug-induced liver injury in Oncology حسب Alejandro D. Ricart

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar<scp>PF</scp>‐05280014 with trastuzumab in healthy volunteers (<scp>REFLECTIONS B</scp>327‐01)

    A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar<scp>PF</scp>‐05280014 with trastuzumab in healthy volunteers (<scp>REFLECTIONS B</scp>327‐01) حسب Donghua Yin, Kerry Barker, Ruifeng Li, Meng Xu, Steven D. Reich, Alejandro D. Ricart, Dan Rudin, Carrie Turich Taylor, Charles Zacharchuk, Arne G. Hansson

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

    Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study حسب Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu, Kyle D. Holen, Garry Schwartz, Mark R. Albertini, Geoffrey R. Weiss, Salim Yazji, Chee M. Ng, George Wilding

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

    Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure حسب Philippe Armand, Margaret A. Shipp, Vincent Ribrag, Jean‐Marie Michot, Pier Luigi Zinzani, John Kuruvilla, Ellen Snyder, Alejandro D. Ricart, Arun Balakumaran, Shelonitda Rose, Craig H. Moskowitz

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

    Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors حسب Brian I. Rini, Joan H. Schiller, John P. Fruehauf, Ezra E.W. Cohen, Jamal Tarazi, Brad Rosbrook, Angel H. Bair, Alejandro D. Ricart, Anthony J. Olszanski, Kristen J. Letrent, Sinil Kim, Olivier Rixe

    منشور في 2011
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies

    Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advance... حسب Monica Mita, Alain C. Mita, Quincy Chu, Eric K. Rowinsky, Gerald J. Fetterly, M. Goldston, Amita Patnaik, Lesley Mathews, Alejandro D. Ricart, Theresa A. Mays, Heather Knowles, Victor M. Rivera, Jeff Kreisberg, Camille L. Bedrosian, Anthony W. Tolcher

    منشور في 2008
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

    Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma حسب Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Yinghua Zhang, Alejandro D. Ricart, Arun Balakumaran, Craig H. Moskowitz

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study

    Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study حسب Craig H. Moskowitz, Pier Luigi Zinzani, Michelle A. Fanale, Philippe Armand, Nathalie A. Johnson, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Eric L. Gustafson, Yinghua Zhang, Alejandro D. Ricart, Arun Balakumaran, Robert W. Chen

    منشور في 2016
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: